Traj18: A Key Regulator of T Cell Development and Function (G28737)

Target Name: TRAJ18

NCBI ID: G28737

TRAJ18

Other Name(s): T cell receptor alpha joining 18

Traj18: A Key Regulator of T Cell Development and Function

T cell receptor alpha-joining 18 (TRAJ18) is a protein that plays a crucial role in the immune system. It is a key regulator of T cell development and function, and is involved in the process of T cell activation and proliferation. Traj18 is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, and lymphoid organs. It is also a potential drug target and biomarker for a variety of diseases.

The immune system is a critical component of the body's defense against infection and disease. T cells, a type of immune cell, are responsible for cell-mediated immunity. T cells are activated when their receptor, Traj18, is recognizes a specific antigen. Once T cells are activated, they divide and differentiate into effector T cells, which release antibodies and other immune molecules to eliminate the invading microorganisms.

Traj18 is a transmembrane protein that is involved in the regulation of T cell development and function. It is a key regulator of the T cell receptor alpha chain, which is responsible for recognizing antigens. The T cell receptor alpha chain consists of several subunits, including the alpha-1 subunit and the alpha-2 subunit. The alpha-1 subunit is the receptor for the antigens that trigger the T cell response, while the alpha-2 subunit is responsible for transmitting the signal from the receptor to the cell.

Traj18 plays a crucial role in the regulation of T cell development and function. It is involved in the process of T cell activation and proliferation. When a T cell encounters an antigen that matches its T cell receptor, Traj18 is activated. Activated Traj18 then interacts with the alpha-1 subunit of the T cell receptor alpha chain, leading to the engagement of the alpha-2 subunit. The alpha-2 subunit then transmits the signal from the receptor to the cell, leading to the activation and proliferation of the T cell.

In addition to its role in T cell development and function, Traj18 is also involved in the regulation of inflammation. Traj18 has been shown to be involved in the regulation of inflammation in various tissues, including the skin and the lymphoid organs.

Traj18 is also a potential drug target and biomarker for a variety of diseases. For example, Traj18 has been shown to be involved in the development of skin cancer, and may be a useful biomarker for monitoring the effectiveness of anti-cancer treatments. Additionally, Traj18 has been shown to be involved in the regulation of inflammation, and may be a useful target for drugs that are designed to treat inflammatory diseases.

Overall, Traj18 is a protein that plays a crucial role in the immune system. It is involved in the regulation of T cell development and function, as well as the regulation of inflammation. As a result, Traj18 is a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of Traj18 in the immune system and its potential as a drug.

Protein Name: T Cell Receptor Alpha Joining 18

The "TRAJ18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets